SICKLE CELL WARRIORS
Imperial’s Sickle Cell Research Group welcomes Sickle Cell Warriors
Researchers at Imperial hosted a visit for children living with Sickle Cell to tour Hammersmith Campus.
Imperial’s Sickle Cell Research Group welcomes Sickle Cell Warriors
Researchers at Imperial hosted a visit for children living with Sickle Cell to tour Hammersmith Campus.
Immunosuppressing medicine can be interrupted to boost COVID-19 vaccine response
Interrupting treatment of immunosuppressing medicines for two weeks can significantly improve antibody immunity provided by COVID-19 booster vaccines.
Hidden way for us to feel touch uncovered by Imperial researchers
Imperial researchers have discovered a hidden mechanism within hair follicles that allow us to feel touch.
4
Imperial expert’s book explains why our gut microbiome matters
An Imperial surgeon specialising in the gut microbiome has published a new book to explain why it is important for our health.
NK:IO raises further investment for cell therapy targeting ovarian cancer
Imperial startup NK:IO has raised an additional £1.2m, in a funding round led by Cancer Research Horizons, the innovation arm of Cancer Research UK.
Natural killer cell therapy under development by new Imperial startup
Harnessing specialised cells from the body’s immune system promises cheaper, more effective cancer treatments.
Study shows real-world COVID-19 vaccine response in vulnerable patient groups
Data from the OCTAVE study show for the first time COVID-19 vaccine responses for people with immunocompromised or immunosuppressed conditions.
Three Imperial researchers awarded AMS Fellowships
Three leading Imperial researchers have been elected to the Fellowship of the Academy of Medical Sciences for their outstanding work in their fields.
Q&A: Does diabetes mean worse outcomes for cancer patients?
Diabetes is a known risk factor for developing cancer, but could it also predict how cancer patients respond to treatment?
First-line defences against COVID-19 are short-lived and may explain reinfection
A new study finds that antibodies produced in the nose decline 9 months after infection, while those found in the blood last at least a year.